FRFabiana Roveda

Fabiana Roveda

*This is an algorithmically generated author record based on publicly available information.

Fabiana Roveda has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Bioequivalência de Levetiracetam 1000mg em voluntários saudáveis

    by Fabiana Roveda, Ligia de Cassia Val, Natalia Cristina Morici Aoki, Barbara de Moraes Silva, Monica Siqueira Ferreira, Leny Damiani de Moraes Leonardi Etlinger

    Introdução. O levetiracetam é um antiepiléptico de segunda geração utilizado no tratamento de crises epilépticas, caracterizado por alta biodisponibilidade, farmacocinética linear, baixa ligação proteica e mecanismo de ação mediado pela proteína SV2A. Em fármacos de uso contínuo como os antiepilépticos, a demonstração de bioequivalência é essencial para garantir estabilidade de exposição sistêmica, segurança e intercambialidade terapêutica. No Brasil, Etira® 1000mg comprimido revestido é referência para levetiracetam, exigindo avaliação comparativa rigorosa conforme diretrizes da ANVISA. Objetivo. Avaliar a bioequivalência entre Levetiracetam 1000mg comprimido revestido (teste) e Etira® 1000mg (referência), administrados sob jejum em voluntários saudáveis. Método. Estudo aberto, randomizado, cruzado 2×2, dose única oral de 1000 mg após jejum mínimo de 8 horas. Concentrações plasmáticas determinadas por LC-MS/MS validado até 36 horas pós-dose. Parâmetros primários: Cmax e AUC₀–t. Bioequivalência demonstrada se IC90% das razões geométricas teste/referência estiver na faixa 80–125%, conforme diretrizes nacionais e internacionais. Resultados. Perfis de concentração plasmática comparáveis. Razões geométricas: Cmax 99,07% (IC90%: 92,95–105,58%) e AUC₀–t 101,41% (IC90%: 98,77–104,11%). Ambos parâmetros dentro da faixa regulatória. Formulações bem toleradas, sem eventos adversos graves. Conclusão. O medicamento teste demonstrou bioequivalência ao referência, suportando intercambialidade terapêutica e consistência biofarmacêutica.

  • Open Access

    Bioequivalence of two formulations of 750 mg levetiracetam extended-release coated tablets in healthy volunteers under fasting and fed conditions

    by Camila Kaori Aihara, Ligia Cássia Val, Natália Cristina Aoki, Fabiana Roveda, Pratikkumar Asari, Naba Kumar Talukdar

    Objective: To evaluate the bioequivalence of the two formulations of Eurofarma’s Levetiracetam 750 mg Extended Release Coated Tablets (Test Product [T]) against Keppra XR (Reference Product [R]) in healthy adults under fasting and fed conditions. Methods: The studies were designed as open, randomized, balanced, two treatments, two-period, single dose, crossover under fasting and fed condition with seven days washout interval. The assigned subjects were given test tablets and reference tablets in each period orally at a dose of 750 mg under fasting and fed conditions. Each study involved 32 subjects. In both the studies under fasting and fed conditions, the major pharmacokinetic parameters were calculated by SAS® Software 9.4 and the bioequivalence was evaluated. Results: For bioequivalence evaluation a total of 31 subjects completed the fasting study, and 29 subjects completed the fed study. The 90% confidence intervals for the geometric mean ratios of Levetiracetam area under the curve (AUC0-T and AUC0-∞) and maximum plasma concentration (Cmax ) were within the established bioequivalence limits of 80% to 125%. A total of three adverse events were reported during the conduct of the two studies, with one event possibly related to the study medication and the other two considered unrelated. All adverse events were mild to moderate in severity and did not significantly impact the participants’ quality of life. No serious adverse events were reported. Conclusion: It can be concluded that the two formulations can be used interchangeably.

  • Open Access

    IMPACT OF HEARTBURN AND REGURGITATION ON INDIVIDUALS’ WELL-BEING IN THE GENERAL POPULATION: A BRAZILIAN NATIONAL SURVEY

    by Joaquim Prado P Moraes-Filho, Gerson Domingues, Decio Chinzon, Fabiana Roveda, Abner Augusto Lobão Neto, Schlioma Zaterka

    BACKGROUND: Heartburn and acid regurgitation are typical symptoms usually associated with gastroesophageal reflux disease (GERD). GERD is one of the gastrointestinal diagnosis with higher prevalence worldwide, significantly impairing patients’ quality of life. OBJECTIVE: The objective of this study was to analyze the impact of GERD-related symptoms in the Brazilian urban population. METHODS: National telephone survey with community-dwelling Brazilian individuals. Self-reported prevalence and frequency of symptoms (heartburn / regurgitation) were assessed. Individuals rated the impact of symptoms in their general well-being using a numeric scale from 1 to 10 (1 = no impact; 10 = very intense, preventing the person to eat and perform daily routine activities). Descriptive and bivariate statistical analyses were performed. RESULTS: The final sample was comprised of 1,773 subjects, 935 (52.7%) females, an average of 40 years old. The prevalence of heartburn and regurgitation in the past 6 months was 26.2% (n=466) and 11.0% (n=196), respectively. Women presented higher prevalence (heartburn n=266, 28.5% and regurgitation n=119, 12.7%) than men (n=200, 23.1% and n=78, 8.9%, respectively) (P<0.05). Heartburn in the past week was reported by 175 individuals (9.8%), while regurgitation episodes by 67 (3.8%). Absence of impact of the symptom in the overall well-being was observed for 82 subjects (17.6%) with heartburn and 18 individuals (9.2%) with regurgitation. Very intense impact was reported by 46 subjects (9.8%) with heartburn and 41 (20.9%) with regurgitation. Women’s well-being was more affected than men’s (mean score 5.45 vs 4.71, P<0.05). CONCLUSION: Heartburn and regurgitation were frequent symptoms, women with higher prevalence. These symptoms led to a substantial impact on individuals’ well-being, women being more affected.


  • Open Access

    BRAZILIAN PHYSICIANS’ PRACTICES ON THE MANAGEMENT OF SYMPTOMS SUGGESTING GASTROESOPHAGEAL REFLUX DISEASE: A MULTIDISCIPLINARY SURVEY

    by Decio Chinzon, Joaquim Prado P Moraes-Filho, Gerson Domingues, Fabiana Roveda, Abner Augusto Lobão Neto, Schlioma Zaterka

    BACKGROUND: Clinical guidelines are available to steer decisions regarding diagnosis, management and treatment of gastrointestinal disorders. Despite this, variations in physician’s practices regarding gastroesophageal reflux disease (GERD) symptoms are well described in the literature. OBJECTIVE: To describe practices of physicians from different specialties on the management of patients with typical symptoms of GERD (heartburn and regurgitation) in a Brazilian sample. METHODS: National online survey enrolling a sample of general practitioners, gastroenterologists, cardiologists and otolaryngologists. The survey was conducted from August 6th to September 12th, 2018. Subjects answered a structured questionnaire addressing variables regarding physicians’ profile (age, sex, specialty, practice setting, years in practice, type of medical expense reimbursement), their patients characteristics and prescribing behaviors. RESULTS: The final weighted sample was comprised of 400 physicians, 64% male, with an average of 15 years of experience. Physicians’ estimates of gastroesophageal symptoms prevalence among their pool of patients was 37.6% for the total sample, reaching 70.3% among gastroenterologists. The medical specialty with lower average percentage of patients presenting gastroesophageal symptoms was otolaryngology (24.5%). Physicians reported that they request ancillary tests for 64.5% of patients with GERD typical symptoms. The most common diagnostic test was endoscopy (69.4%), followed by video nasolaryngoscopy (16.6%). The percentage of patient to whom endoscopy is performed was significantly higher among gastroenterologists and general practitioners as compared to otolaryngologists and cardiologists, while video nasolaryngoscopy is markedly more frequent among otolaryngologists. In terms of therapeutic options, the most frequently reported strategy was lifestyle modifications followed by proton pump inhibitors. CONCLUSION: Overall patients’ profile and patterns of GERD diagnosis and management seem different between gastroenterologists, general practitioners, otolaryngologists, and cardiologists. Clinical guidelines should address this variability and include other medical specialties besides gastroenterologists in their scope.


  • Open Access

    HISTORICAL PERSPECTIVE OF GASTROESOPHAGEAL REFLUX DISEASE CLINICAL TREATMENT

    by Schlioma Zaterka, Sandra Beatriz Marion, Fabiana Roveda, Marcos Antônio Perrotti, Decio Chinzon

    BACKGROUND: Gastroesophageal reflux disease (GERD) is one of the most prevalent gastrointestinal diseases. GERD generates significant impairment in patients’ quality of life and it is associated to relevant medical resources utilization. A better understanding of GERD pathophysiology in the past five decades has favored the evolution of therapeutic strategies from non-drug interventions and antacids to more efficacious and safer alternatives. OBJECTIVE: To summarize data about the historical evolution of GERD management in Brazil, focusing on medical therapy and addressing evidence on efficacy and safety of drug classes currently recommended. METHODS: A narrative review was conducted by systematizing information about discoveries on GERD pathophysiology. We also addressed efficacy and safety of medications currently used to reduce symptoms and improve endoscopic healing of esophageal lesions. A structured search on Pubmed was performed to identify systematic reviews and meta-analysis investigating GERD outcomes positively impacted by proton pump inhibitors (PPIs), the first choice of pharmacotherapy for the disease. RESULTS: The chronological development of therapeutic measures for GERD in Brazil evolved from lifestyle interventions with relative poor effect on symptoms related to esophageal acid exposure, particularly heartburn, to effective and safe pharmacological interventions such as histamine H2-receptor antagonists and PPIs. In the present days, some drug classes play a minor role in disease management, namely prokinetics and antacids, due to their reduced efficacy and relevant safety concerns (particularly with prokinetics). The main challenge for prescribers and researchers seems to be finding long-acting acid suppressants strategies able to ameliorate patients’ symptoms and quality of life, thereafter, reducing medical resource consumption. The dual delayed-release PPI dexlansoprazole seems to respond for some of the limitations other PPIs have. CONCLUSION: Recognizing the historical evolution of GERD management can help care providers to better understand therapeutic options for their patients, as well as focus on unmet needs that deserve further attention. PPIs are still the first choice therapy, with good evidence in favor of their efficacy, despite some safety concerns. However, as with any medical intervention, it is recommended to prescribe PPIs for patients with clear indication, using adequate dosing and monitoring for adverse events.